We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FNV:NYSEFranco-Nevada Corporation Analysis

Data as of 2026-04-04 - not real-time

$257.74

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Franco‑Nevada is trading well above its 20‑day, 50‑day and 200‑day SMAs at $257.74, with the MACD histogram turning positive and the MACD signal flagged as bullish, suggesting short‑term momentum remains intact. Revenue surged 86% year‑over‑year to $1.8 B and margins are exceptionally high (gross >90%, operating >75%), while the company carries no debt and holds $670 M in cash, underscoring a strong balance sheet. However, the DCF‑derived fair value of roughly $204 implies the stock is currently overvalued relative to intrinsic estimates, a gap reflected in the 19% upside/downside metric and a forward P/E still above 25. The dividend yield is modest at 0.68% with a low payout ratio (~26%), indicating sustainability but limited income appeal. Analyst sentiment is upbeat, with a median 12‑month price target of $306 and a recent upgrade to $305, while the Fear & Greed Index sits at “Extreme Greed,” signaling heightened market optimism.
Geographically, the royalty portfolio spans North and South America, Europe, Africa and Australia, exposing the firm to diverse political and currency environments, yet its beta under 0.5 and stable volume suggest muted price sensitivity. High 30‑day volatility (~44%) and a max drawdown near 21% temper the bullish outlook, making risk management essential as the stock approaches a technical resistance around $269.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Positive MACD histogram and price above short‑term SMAs
  • Current price near technical resistance at $269
  • Overvaluation relative to DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust 86% revenue growth and ultra‑high profit margins
  • Analyst consensus price target near $306
  • Debt‑free balance sheet with strong cash position

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable royalty and streaming streams across multiple jurisdictions
  • Low dividend payout ratio supporting cash preservation
  • Elevated valuation and commodity price volatility

Key Metrics & Analysis

Financial Health

Revenue Growth85.80%
Profit Margin61.64%
P/E Ratio44.8
ROE16.32%
ROA11.54%
P/B Ratio6.5
Op. Cash Flow$1.5B
Free Cash Flow$-1066712512

Technical Analysis

TrendNeutral
RSI57.5
Support$219.10
Resistance$269.33
MA 20$245.96
MA 50$251.92
MA 200$208.02
MACDBullish
VolumeStable
Fear & Greed Index78.8

Valuation

Fair Value$204.20
Target Price$305.90
Upside/Downside18.69%
GradeOvervalued
TypeGrowth
Dividend Yield0.68%

Risk Assessment

Beta0.47
Volatility43.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.